SpaceX's Lockup Expires Tomorrow: 912 Million Insider Shares Meet the Market

The lockup clock runs out tomorrow

When SpaceX priced its IPO at $135 a share on June 11 and began trading the next morning, it sold roughly 639 million shares — about 5% of the company — and raised $86 billion in the largest public offering on record^[1]. That left the other 95% locked up, held by employees, early investors, and insiders who agreed not to sell for defined periods. Tomorrow, August 6, the first major lockup expires, and up to 911.5 million Class A common shares become eligible for sale^[1].

That number — 911.5 million — exceeds the entire IPO float by roughly 43%. Put differently, the tradable supply of SpaceX shares could nearly quadruple in a single day^[1].

The timing is deliberate, and uncomfortable. SpaceX delivered its first earnings report as a public company on August 4, and the lockup was structured to expire two business days later, on August 6^[2]. That means insiders who have held shares for years at a very low cost basis get their first chance to monetize immediately after the market has seen the company’s numbers.

SpaceX’s debut earnings: a beat with a catch

The Q2 report was, on the surface, strong. SpaceX reported revenue of $7.81 billion against Wall Street consensus of $6.93 billion — a 92% jump from $4.1 billion a year earlier^[3]. Adjusted EBITDA came in at $3.5 billion, up 191% year over year, and the net loss of $541 million was narrower than the loss per share of 26 cents analysts had modeled (the actual loss per share was 9 cents)^[3].

But the stock dropped roughly 7–8% in extended trading^[3]. The catalyst was capital expenditure: SpaceX’s AI and infrastructure spending ran above what investors had penciled in, and the market used the first look under the hood to reprice the cost of the growth story^[3].

That after-hours decline compounds a brutal run since the IPO’s opening weeks. The stock hit an intraday high of $225.64 on June 16 — a 67% pop from the offering price — before sliding for eight of nine sessions through mid-July, closing at $131.11 on July 17, below the $135 IPO price^[1]. At its closing high, the company carried a paper valuation of $2.64 trillion^[1]. The drawdown from peak to that mid-July close was roughly 42%.

The lockup structure: a staggered avalanche

This is not a one-day event. SpaceX has what Renaissance Capital senior strategist Matthew Kennedy called “the longest series of lock-up releases we’ve ever seen”^[2].

The schedule, based on SEC filings, runs as follows:

Most of these expirations do not cover shares held by CEO Elon Musk, certain top executives, and board members — those become eligible in early June 2027, though Musk has said he does not plan to sell^[2].

The contingent tranche is worth noting. If the stock had been trading above $175.50 around the earnings window, an additional 455.8 million shares would have unlocked — bringing the first wave to roughly 1.37 billion shares^[1]. At the stock’s current trajectory well below that level, that tranche likely stays locked for now. But the $175.50 trigger embedded in the filing signals that the company’s underwriters expected, or at least allowed for, a scenario where the stock held above that level. It didn’t.

The float arithmetic and the index fund question

The core market-structure question is whether demand can absorb the supply. Here the numbers cut both ways.

On the demand side, index funds will be forced buyers. SpaceX was fast-tracked into the Nasdaq 100 shortly after its debut, ensuring steady purchases from index-based investors^[1]. As the float expands, SpaceX’s float-adjusted market capitalization rises, and its weighting in cap-weighted indices increases in lockstep. Morningstar analyst Zachary Evens pointed to the Invesco QQQ Trust (QQQ), which held roughly 39.7 million SpaceX shares worth $4.57 billion as of July 22 — a 0.98% portfolio weight^[2]. If the float-adjusted market cap triples (as it could by end of September if the contingent tranche unlocks), the Nasdaq would treat SpaceX as roughly a $675 billion company, placing it between Walmart and Intel in the QQQ portfolio^[2].

On the supply side, the selling pressure is real. Morningstar’s SpaceX analyst Nicolas Owens noted that “most of the available shares will come to market, because the existing sellers have low cost basis and long holding periods”^[2]. Translation: insiders sitting on multi-bagger gains have strong incentives to diversify.

The honest forecast is a 60/40 call that the supply outweighs demand in the near term. As Owens put it: “Unless something changes the fundamental story or sentiment — like for the better — the supply from these lockups will outweigh demand even from index funds”^[2]. The 40% case for the other direction: if the stock has already discounted the lockup overhang (it’s down 42% from peak), and if the index rebalancing mechanics generate enough forced buying, the net selling pressure could be lighter than the raw share count implies.

What the broader IPO calendar shows

SpaceX is the headline, but it’s not the only issuance story this week.

Attovia Therapeutics (ATTO) priced its upsized IPO on August 4 at $17 per share, selling 17 million shares for $289 million in gross proceeds^[4]. The Goldman-backed clinical-stage biotech focused on immune-mediated diseases priced at the top of its marketed range and lists on Nasdaq today, August 5^[4]. It’s a reminder that even as the SpaceX lockup dominates attention, the new-issue market remains open for business.

Meanwhile, in Asia, CXMT (ChangXin Memory Technologies), China’s largest memory chipmaker, raised $8.6 billion in the continent’s biggest 2026 IPO on the Shanghai STAR Market on July 27^[5]. Shares surged 466–472% on their first trading day, vaulting CXMT to China’s most valuable listed company by market capitalization — roughly 3.3 trillion yuan ($487 billion)^[5]. The deal was the largest ever by a mainland Chinese issuer and underscores that the appetite for large-cap tech IPOs, at least in Asia, remains voracious.

The market-structure backdrop

The SpaceX lockup arrives against a broader structural shift in equity markets. Citadel Securities’ 1H 2026 review described the defining story of the year as “the structural transformation of equity markets” — driven by concentration, the rise of passive investing, and retail participation^[6]. Liquidnet’s Q2 2026 US Liquidity Landscape report found that trading has shifted back toward lit venues while off-exchange behavior continues to evolve, and macro uncertainty is making institutional execution conditions more challenging^[6].

For SpaceX specifically, the lockup release is a natural experiment in how a stock with a tiny initial float and enormous index-fund demand absorbs a sudden, large supply shock. The Nasdaq 100 fast-tracking meant index funds were buying from day one; now they’ll be buying more as the float expands. But the question is whether that structural demand — mechanical, price-insensitive, and driven by index rebalancing — can keep pace with discretionary insider selling that is, by definition, motivated by a desire to lock in gains.

What to watch next

1. August 6 open: The first minutes of trading after the lockup expires. Volume spike and order-book depth will signal whether sellers rush in or drip out. Watch the bid-ask spread widening as a proxy for absorption stress.

2. The $175.50 trigger: Whether the contingent 455.8-million-share tranche unlocks around August 20. At current prices well below that level, it likely stays locked — but if the stock rallies into the window, that tranche could suddenly double the supply overhang.

3. Index fund rebalancing timing: Index providers typically review float quarterly, not in real time. The lag between lockup expiry and the next rebalancing creates a window where supply hits the market before index demand catches up. Watch for the next Nasdaq 100 float adjustment date.

4. September lockup tranches: Further expirations are on deck. If August 6 doesn’t clear the selling pressure, the market will face another wave next month.

5. Musk’s commentary: The CEO has said he doesn’t plan to sell when his shares become eligible in June 2027, but any change in that stance — or any signaling about other insiders’ intentions — would move the stock.

The base case here is that the lockup supply outweighs index fund demand in the weeks ahead, putting downward pressure on a stock that has already given back 42% from its peak. The risk to that forecast is that the selling was already front-run — the stock’s slide below the IPO price in mid-July may have been the market discounting the lockup in advance, in which case the actual event could be a “sell the rumor, buy the news” moment. Either way, the next several trading sessions will tell us whether the market’s appetite for SpaceX extends beyond the constrained 5% float that made the IPO pop in the first place.